GSK (OTC: GLAXF) leaders add shares via company reward plan

Rhea-AI Filing Summary

GSK plc filed a report showing several senior leaders acquiring small amounts of GSK ordinary shares through the company’s Share Reward Plan. On 2025-10-09, CEO Emma Walmsley acquired 14 ordinary shares (7 partnership and 7 matching shares) at £16.4083 per share on the London Stock Exchange. CFO Julie Brown, Group General Counsel James Ford, President Corporate Development David Redfern, President Global Supply Chain Regis Simard, President Global Affairs Philip Thomson, and ViiV Healthcare CEO and President Global Health Deborah Waterhouse each acquired 16 shares under the plan at the same price. SVP Global Communications Sally Jackson and SVP & Company Secretary Victoria Whyte each acquired 14 shares on the same terms.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	7 (partnership shares)
			£16.4083	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	8 (partnership shares)
			£16.4083	8 (matching shares)
		d)	Aggregated information
Aggregated volume Price	16 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	8 (partnership shares)
			£16.4083	8 (matching shares)
		d)	Aggregated information
Aggregated volume Price	16 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	7 (partnership shares)
			£16.4083	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	8 (partnership shares)
			£16.4083	8 (matching shares)
		d)	Aggregated information
Aggregated volume Price	16 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	8 (partnership shares)
			£16.4083	8 (matching shares)
		d)	Aggregated information
Aggregated volume Price	16 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	8 (partnership shares)
			£16.4083	8 (matching shares)
		d)	Aggregated information
Aggregated volume Price	16 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	8 (partnership shares)
			£16.4083	8 (matching shares)
		d)	Aggregated information
Aggregated volume Price	16 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4083	7 (partnership shares)
			£16.4083	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: October 10, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider transactions did GSK (GLAXF) report in this filing?

The filing reports multiple GSK senior executives acquiring small amounts of ordinary shares under the company’s Share Reward Plan, all executed on 2025-10-09 on the London Stock Exchange.

How many GSK shares did CEO Emma Walmsley acquire?

Emma Walmsley acquired a total of 14 ordinary shares, consisting of 7 partnership shares and 7 matching shares, at a price of £16.4083 per share.

What did GSK CFO Julie Brown purchase under the Share Reward Plan?

Julie Brown acquired 16 ordinary shares in total, comprising 8 partnership shares and 8 matching shares, at £16.4083 per share under GSK’s Share Reward Plan.

Which other GSK executives acquired shares and in what amounts?

James Ford, David Redfern, Regis Simard, Philip Thomson, and Deborah Waterhouse each acquired 16 ordinary shares. Sally Jackson and Victoria Whyte each acquired 14 ordinary shares, all via the Share Reward Plan.

What type of GSK security was acquired and on which market?

The executives acquired GSK ordinary shares of 31 ¼ pence each (ISIN GB00BN7SWP63), and the transactions were conducted on the London Stock Exchange (XLON).

At what price were the GSK ordinary shares acquired by management?

All reported acquisitions were made at a price of £16.4083 per ordinary share under the company’s Share Reward Plan.

Is this GSK filing related to a share sale or a purchase by insiders?

The transactions disclosed are acquisitions of GSK ordinary shares by senior executives through the company’s Share Reward Plan, not sales.